RC48 with chemotherapy for HER2-positive advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether combining the drug RC48 with chemotherapy can help people whose HER2-positive advanced breast cancer has stopped responding to a prior type of antibody-drug conjugate (ADC) therapy. It may offer a new treatment option for those whose cancer has progressed after previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman aged 18 or older.
- Your cancer must be HER2-positive (tested with IHC 3+ or IHC 2+ and FISH positive) and advanced (has spread or cannot be removed by surgery).
- Your cancer must have worsened while on or after treatment with a type of targeted therapy called a TOP1i-ADC (like T-DXd or sacituzumab govitecan).
- You must have had no more than 3 previous treatments for advanced disease, and only one type of ADC before.
- You must have at least one measurable tumor outside the brain that can be evaluated by scans.
- You must have good overall health, with an ECOG performance status of 0 or 1, and adequate organ function (blood counts, liver, kidneys).
- If you can become pregnant, you must use medically approved contraception during the study and for at least 3 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests RC48, an antibody-drug treatment, for people with advanced breast cancer that cannot be cured or removed, specifically HER2-low (or HER2-ultralow) tumors. It may help by targeting cancer cells with this “HER2-low” trait while limiting spread in the body.
This trial tests a new combination of drugs (RC48 plus either Avastin or Pyrotinib) for people with HER2-positive breast cancer that has spread and has stopped responding to the drug T-DXd. The goal is to see if these combinations can help shrink tumors and control the cancer longer.
This study tests a combination of three treatments for advanced stomach cancer that is HER2-positive. The treatments are RC48, an antibody-drug conjugate that targets HER2 on cancer cells, sintilimab, which helps the immune system fight cancer, and S-1, a chemotherapy drug. The goal is to see if the combination is safe and effective as a first-line treatment.
This Phase 1 study tests a HER2-targeted antibody drug (RC48-ADC) given with radiation in people with locally advanced solid tumors that cannot be removed by surgery. It aims to find a safe way to use the treatment and see how well it works in cancers that have HER2 protein on their cells.
This trial tests a combination of two drugs, disitamab vedotin and bevacizumab, for people with a specific type of advanced breast cancer called HER2-low. It is designed for those who have already been treated with a drug called T-DXd and need further options.
This trial tests a new combination of targeted drugs (Disitamab Vedotin and RC148) against a standard chemotherapy (Abraxane) with or without an immunotherapy drug (Toripalimab) for advanced breast cancer that is HER2-low and hormone receptor-negative. The goal is to see if the new combination works better at shrinking tumors and slowing cancer growth.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.